Nuclear factors of activated T cells (NFAT) are critical modulators of cancer cell growth and survival. However, the mechanisms of their oncogenic dysregulation and strategies for targeting in tumors remain elusive. Here, we report coupling of anti-apoptotic NFAT (NFAT2) activation to cholesterol-enriched lipid raft microdomains of malignant melanoma cells and interruption of this pathway by the aminobisphosphonate zoledronic acid (Zol). The pathway was indicated by capability of Zol to promote apoptosis and to retard in vivo outgrowth of tumorigenic melanoma cell variants through inhibition of permanently active NFAT2. NFAT2 inhibition resulted from disintegration of cholesterolenriched rafts due to reduction of cellular cholesterol by Zol. Mechanistically, raft disruption abolished raft-localized robust store-operated Ca 2+ (SOC) entry, blocking constitutive activation of protein kinase B/Akt (PKB) and thereby reactivating the NFAT repressor glycogen synthase kinase 3β (GSK3β). Pro-apoptotic inactivation of NFAT2 also followed reactivation of GSK3β by direct inhibition of PKB or SOC, whereas GSK3β blockade prevented Zol-induced NFAT2 inhibition and cell death. The rescuing effect of GSK3β blockade was reproduced by recovery of entire SOC/PKB/GSK3β cascade after reconstitution of rafts by cholesterol replenishment of Zol-treated tumorigenic cells. Remarkably, these malignant cells displayed higher cholesterol and lipid raft content than non-tumorigenic cells, which expressed weak SOC, PKB and NFAT2 activities and resisted raft-ablating action of Zol. Together, the results underscore the functional relevance of amplified melanoma rafts for tumor-promoting NFAT2 signaling and reveal these distinctive microdomains as a target for in vitro and in vivo demise of tumorigenic cells through NFAT2 inhibition by the clinical agent Zol.
Introduction

Ca
2+ -dependent nuclear factors of activated T cells proteins (NFAT1-4) are emerging as attractive targets for cancer therapy. These transcription factors drive expression of distinct sets of genes, associated with aggressive cancer phenotype (1, 2) . Consequently, one of the NFAT isoforms, i.e. NFAT2, readily transforms non-neoplastic cells and renders these cells tumorigenic when expressed in permanently active form (1, 2) . Pertinent to human pathology, constitutive nuclear localization and activation of NFAT2 and/or NFAT1 occurs in hematological malignancies (1, 2) , pancreatic (1-3), breast (1, 2, 4) and hepatocellular carcinomas (1, 2, 5) , glioblastoma (6) and in malignant melanoma cells (7, 8) . Rare incidence of mutations in these isoforms (1, 2) suggests linking of their hyper-activity to up-stream signal events that either drive to or retain NFAT in the nucleus. For instance, robust function of store-operated Ca 2+ (SOC) channels, stimulating nuclear translocation of NFAT through the action of calcineurin phosphatase (1, 2) , has been reported in cancer types with NFAT abnormalities (9) (10) (11) (12) (13) . Cancer cells also frequently display elevated basal activity of protein kinase B/Akt (PKB) (14) , which is a negative modulator of the NFAT repressor glycogen synthase kinase 3β (GSK3β) (15, 16) . However, the exact mechanisms of oncogenic NFAT dysregulation and strategies for their targeting in tumors are largely unknown. In fact, the available blockers of NFAT activity, the calcineurin inhibitors cyclosporine A and tacrolimus, impair growth and survival of malignant cells in vitro, but suppress anti-cancer immunity and promote tumor development in vivo (1, 2, 17, 18) .
The structural and biochemical properties of cholesterol-enriched plasmalemmal microdomains (lipid rafts) result in selective retention of certain classes of membrane-associated molecules, such that rafts promote interactions between discrete subsets of signal intermediates and thereby signal transduction (19) . In cancer cells, lipid rafts are viewed as important linchpins, from which signals essential for invasive growth, resistance to death-inducing stimuli and other malignant characteristics are launched (20, 21) . Thus, we reported that in malignant melanoma cells, hyper-activity of PKB is sustained by robust SOC-mediated Ca 2+ entry, occurring in raft microdomains (22, 23) . Ablation of rafts with the membrane cholesterol-extracting oligosaccharide methyl-β-cyclodextrin interrupted the SOC/PKB axis and impaired survival of melanoma cells and their tumorigenicity in animals (22, 23) . In the present research, we address coupling of this raft-driven pathway via GSK3β to NFAT and feasibility of its targeting with the clinical agent zoledronic acid (Zol). Our study focused on Zol for the following reasons. Besides the efficacy against bone disorders including cancer-induced osteolysis, Zol has been reported to directly inhibit skeletal and extra-skeletal outgrowth of certain experimental malignancies through induction of apoptosis and/or growth arrest in neoplastic cells (24) (25) (26) (27) (28) (29) . In preclinical models of pancreatic and breast carcinoma models, Zol readily inhibited NFAT in both cancer cell types (28) , though the precise mode of interference with tumor-promoting signaling by this drug is poorly understood. Nevertheless, it is known that at cellular level, Zol blocks the mevalonate pathway enzyme farnesyl diphosphate synthase and depletes cholesterol among other mevalonate pathway metabolites (24, 29) . Cholesterol depletion is expected to alter raft integrity, but capability of Zol to ablate rafts and thereby raft-driven signal events has not previously been explored. Here, we report amplification of lipid rafts in tumorigenic melanoma cell variants that maintains constitutive NFAT (NFAT2) activity through enhancement of raft-localized SOC, SOC-dependent PKB activity and PKB-mediated GSK3β blockade. By disrupting amplified rafts of these malignant cells but not microdomains of non-tumorigenic cells, Zol inactivates NFAT2 in vitro and in vivo that facilitates apoptosis and significantly attenuates melanoma tumor growth.
Materials and methods
Cell culture and plasmids
Murine melanoma cells (B16BL6-8, Kb30, JB/RH1) (9, 22, 30) were provided by Prof. E.Gorelik (University of Pittsburgh, Pittsburgh, PA) and human GA melanoma clone (31) by Prof. J.Gopas (Ben-Gurion University, Beer-Sheva, Israel). GA-PLXR cells were established by treating GA cells with PLX4720 (3 µM) for 90 days. Cells were grown in RPMI medium supplemented by 10% bovine serum and antibiotics. Tissue culture reagents were purchased from Biological Industries (Beth Haemek, Israel) and Zol and PLX4720 from MedKoo Biosciences (Chapel Hill, NC (murine: TI336190) small hairpin RNA (shRNA)-encoding plasmids were purchased from Sigma and Origene (Rockville, BD), respectively. Renilla luciferase construct was purchased from Promega (Madison, WI). All transfections were carried out using the Arrest-In reagent according to the protocol provided by the manufacturer (Open Biosystems, Huntsville, AL). Cells were maintained in serum-supplemented media for 24 h post-transfection and then under serum-free conditions for additional time intervals (48-96 h) detailed in the text. The amount of each plasmid was ~0.5 µg/0.3-0.5 × 10 6 cells, except anti-murine and anti-human shRNA constructs applied at ~0.8 µg/0.3-0.5 × 10 6 and ~1 µg/0.3-0.5 × 10 6 , respectively, and Renilla luciferase construct applied at ~0.1 µg/0.3-0.5 × 10
6 . Co-transfection of more than three distinct plasmids produced non-specific toxicity in all melanoma cell types, except B16BL6-8 cells (S.Fedida-Metula, unpublished observation). Therefore, such experiments (Figures 4 and 5) employed B16BL6-8 cells only.
Analyses of cell cycle, SOC function, cholesterol content and levels of liquid-ordered rafts by flow cytometry
Cellular DNA measurements were performed by staining cells, fixed in 70% ethanol, with propidium iodide (10 µg/ml; Sigma), as described (9, 22) . To assess SOC function, Fluo4-AM-loaded (2.5 µM, 30 min, room temperature; Invitrogen, Eugen, OR) cells were suspended in Ca 2+ -free Ringer solution (20 mM N-2-hydroxyethylpiperazine-N ' 2-ethanesulfonic acid, pH 7.4, 120 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl 2 and 15 mM glucose). Samples were run for ~60 s, thapsigargin (2 µM; Sigma) was added and CaCl 2 (2 mM) applied at the end of thapsigargin-induced fluorescence peak, as described (9, 23) . Instantaneous fluorescence changes were normalized to the resting values before thapsigargin addition and plotted. For cholesterol measurements, cells fixed in 4% of paraformaldehyde (Sigma) were probed to filipin (20 µg/ ml, 30 min, room temperature; Sigma) and analyzed, as described (23) . For lipid raft analysis, cells were probed to di-4-ANEPPDHQ (5 µM, 30 min, room temperature; Invitrogen) in phosphate-buffered saline, washed with phosphatebuffered saline and immediately analyzed. Lipid raft levels were expressed as a ratio between ANE signals, emitted from liquid-ordered (560 nm; raft) and non-ordered (620 nm; non-raft) membrane phases. All experiments were performed using the FACSCanto II instrument (BD Biosciences, San Jose, CA) and data processed with the FloJo software.
Animal experiments and histochemical analysis of tumor specimens Study protocol was approved by the Institutional Committee for Ethical Care of Laboratory Animals (Ben-Gurion University of the Negev). C57BL/J and Balbc nu − /nu − mice (8 weeks old; both from Harlan, Jerusalem, Israel) were subcutaneously inoculated into the footpads with 2.5 × 10 5 (B16BL6-8, Kb30) and 1.6 × 10 6 (GA-PLXR, GA) cells in 0.03 ml of sterile saline, respectively. Zol (0.1 and 1 mg/kg) were intraperitoneally administered in 0.3 ml of sterile saline twice a week from day 7 after cancer cell engraftment. Tumorigenicity of JB/RH1 cells was confirmed using protocol applied for B16BL6-8 and Kb30 cells before initiation of the present study. To minimize number of animals for bioethical reasons, isograft experiments with Zol did not include JB/ RH1 cells because of their phenotypic and biochemical similarity to B16BL6-8 cells (9, 22, 30) . Melanoma specimens were collected at day 28 after tumor cell implant, fixed in 4% paraformaldehyde, dehydrated in alcohol, cleared in xylene and embedded in paraffin. Antigen retrieval procedure included boiling for 20 min in 20 mM citrate buffer solution (pH 6). Immunohistochemical studies were performed using anti-pGSK3β (diluted 1:50, 4°C overnight; #9832, Cell Signaling, Beverley, MA) and anti-pAkt (1:50, 4°C overnight; #4058, Cell Signaling) antibodies, as described (23) . Apoptosis was assessed using the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and ApopTag Peroxidase in situ apoptosis detection kit (Merck Millipore, MA) according to the recommendations provided by the manufacturer.
Evaluation of NFAT-driven luciferase reporter
Cells (0.3 × 10 6 ) were seeded onto six-well tissue culture dishes and after 24 h co-transfected with the NFATluc and Renilla luciferase constructs (Promega, Madison, WI). Assay was performed 48 h post-transfection using the Dual Luciferase reporter system and GloMax Single Tube Luminometer (Promega). NFAT activity was expressed as a ratio of NFATluc firefly and Renilla luciferase luminescent signals.
Preparation of total cellular extracts and sub-cellular fractions for western blotting and dot blot analyses
Total cellular extracts were prepared, as described (22) , and subjected to western blotting analysis using anti-NFAT1 (1:200; #7296, Santa-Cruz Biotechnology, Santa-Cruz, CA), anti-NFAT2 (1:200; #7924, Santa-Cruz), anti-NFAT3 (1:200; #8405, Santa-Cruz), anti-NFAT4 (1:200; #271597, Santa-Cruz), anti-pAkt (1:800; #4058, Cell Signaling), anti-pGSK3β (1:1000; #9832, Cell Signaling), anti-PKB (Akt1) (1:200; #5298, Santa-Cruz), anti-GSK3β (1:1000; #9336, Cell Signaling), anti-HA (1:500; #7392, Santa-Cruz) and anti-actin (1:50 000; #691001, MP Biomedicals, Aurora, OH) antibodies. Band intensities were assessed using the ImageJ software. For sub-cellular fractionation (23) , cells suspended in ice-cold buffer [1% Triton X-100, 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 6.9, 100 mM NaCl, 2 mM ethylenediaminetetraacetic acid, 0.2 mM sodium orthovanadate and protease inhibitors] were homogenized using a Dounce glass homogenizer at ice. Large debris and nuclei were removed by centrifugation (400g, 5 min, 4°C). Clear supernatant (0.3 ml) were mixed with equal volume of lysis buffer containing 85% sucrose (wt/ vol), overlaid with 1 ml of 35% sucrose and 0.3 ml of 5% sucrose. Following ultracentrifugation (200 000g, 16 h, 4°C), nine fractions (0.2 ml each) were collected from the top of the gradient and subjected to western blotting and dot blot analyses using anti-Stim1 antibodies (1:500; #52458, Abcam, Cambridge, UK) and horseradish peroxidase-conjugated cholera toxin B subunit (CTXB) (5 µg/ml; Merck, Schwalbach, Germany), respectively.
Fluorescence confocal microscopy analysis of NFAT2 compartmentalization
For NFAT2 studies, cells seeded onto glass cover-slips and fixed in 4% paraformaldehyde (10 min, room temperature), permeabilized in phosphatebuffered saline containing 0.1% of Triton X (1 min, room temperature) and probed to anti-NFAT2 antibodies (1:100, 16 h, 4°C; #2796, Abcam) and cy2-conjugated secondary antibodies (1:200, 3 h, 4°C; Jackson ImmunoResearch, PA). Samples were counter-stained with 7-aminoactinomycin-D (Invitrogen) and analyzed using the LSM510 system [480 excitation laser, 505-545 band pass (cy2) and 560 long pass (7-aminoactinomycin D) filters; Carl Zeiss, Jena, Germany].
Statistical analysis
All analyses were performed using the SPSS software (SPSS for Windows, Version 15.0., SPSS, Chicago, IL). Student's t-test was applied to calculate statistical significance of differences between parameters measured in experimental samples versus controls at time intervals indicated for each particular experiment.
Results
Zol promotes apoptosis in cultured and animal-engrafted tumorigenic melanoma cells and retards melanoma tumor growth
Since tumorigenic melanoma cells can grow in the absence of serum and resist apoptosis triggered by serum starvation (32), we assessed melanoma-suppressive activity of Zol by testing its effect on growth and survival of selected melanoma lines under serum-supplemented and serum-free conditions. For this purpose, we employed murine tumorigenic (B16BL6-8, JB/RH1) and non-tumorigenic (Kb30) melanoma cells (22, 30) . Our study also utilized human non-tumorigenic GA melanoma line (31) and its tumorigenic GA-PLXR variant ( Figure 1D and data not shown). The latter cells were generated by treating GA cells with the BRaf inhibitor PLX4720 (3 µM, 90 days) and were insensitive to PLX4720-induced cytotoxicity (Supplementary Figure 1 , available at Carcinogenesis Online). Concentrations of Zol were in range of 10-50 µM, sufficient for eliciting biological response in cell types other than melanoma (24) (25) (26) 28, 29, 33) . Figure 1A shows steady increase of cell counts in serum-supplemented and serumstarved cultures of tumorigenic cells, whereas deprivation of serum arrested growth of Kb30 cells at 72 h and markedly retarded growth of GA cells. Application of 50 µM but not lower doses of Zol led to ~2-fold reduction of cell counts in serum-supplemented B16BL6-8, JB/RH1 and GA-PLXR cultures, but not in Kb30 and GA cultures, at 72 h of treatment ( Figure 1A ). The effect was more prominent under serum-starved conditions, as it became apparent at 48 h and reached the maximum of ~5-fold inhibition compared to control 72 h upon Zol treatment. The observed reduction of cell counts was paralleled by accumulation of cells with sub-G1 DNA content (apoptotic cells), the percentages of which were approximately two times higher in serum-starved than in serum-supplemented samples ( Figure 1B) . No consistent changes in G 1 , S and G 2 /M phase distribution accompanied Zol-induced apoptosis under serum-starved conditions, while Statistical significance of differences between parameters, measured in control and treated samples at indicated time intervals, was determined using Student's t-test. *P < 0.05, **P < 0.01, ***P < 0.001. a moderate delay in G 1 phase progression in serum-supplemented cultures was unavoidably followed by appearance of sub-G 1 cells ( Figure 1B) . The results indicated that impaired survival manifested by apoptosis and compromised resistance to deprivation of serumderived growth factors was a key response of tumorigenic cells to Zol. Apoptotic nature of cell death was confirmed by detection of collapsed inner mitochondrial membrane potential (ΔΨ m ) and DNA fragmentation (Supplementary Figure 2 , available at Carcinogenesis Online). To determine the implications of pro-apoptotic action of Zol for in vivo melanoma growth, we employed isograft and xenograft tumor models. Murine (B16BL6-8, Kb30) and human (GA-PLXR, GA) cells were subcutaneously inoculated into the footpads of C57BL/J and Balbc nu − /nu − mice, respectively. Neither Kb30 nor GA cells generated tumors in animals under our experimental conditions (data not shown). B16BL6-8 and GA-PLXR cells formed visible melanin-producing lesions at day 7 after cancer cell implant when vehicle (saline) or Zol (0.1 and 1 mg/kg, twice a week, intraperitoneal) was administered. Both doses were in agreement with sub-acute toxicity data (34) and previous reports on anti-cancer activity of Zol in experimental malignancies (24) (25) (26) (27) (28) . Tumor development was monitored by measuring foot diameter until day 28, when lesions were excised for histochemical evaluation of apoptosis. Remarkably, 1 mg/ kg of Zol strongly attenuated melanoma development, as reflected by slower growth and significantly smaller sizes of tumors compared to the control group ( Figure 1C) . Furthermore, small tumors from Zoltreated animals displayed higher extent of apoptotic TUNEL staining relative to large tumors from control mice ( Figure 1D ). Together, the results underscore capability of Zol to promote apoptosis in cultured and animal-engrafted tumorigenic melanoma cells and suggest that apoptotic response mediates suppression of melanoma tumor growth by this drug.
Zol promotes apoptosis by abolishing constitutively nuclear localization and activation of the NFAT2 isoform of NFAT in tumorigenic melanoma cells
Recent study implicated Zol in modulation of NFAT (28) . Since these transcription factors elicit pro-survival function in many cancer types (1,2), we asked whether Zol promotes apoptosis by inhibiting NFAT. By transfecting cells with the NFAT-driven luciferase reporter construct (NFATluc) and assaying luciferase 48 h thereafter (Figure 2A) , we recorded >4-fold higher basal NFAT activity in tumorigenic than in non-tumorigenic melanoma variants ( Figure 2B ). Application of Zol (50 µM, 24 h) reduced this enhanced NFAT activity to the levels detected in non-tumorigenic cells but did not alter weak NFAT function in the latter cells ( Figure 2B; Supplementary Figure 3 , available at Carcinogenesis Online). Western blotting analysis revealed that NFAT2 dominated over other NFAT isoforms and was expressed at comparable levels in all melanoma variants with no protein loss in Zol-treated tumorigenic cells ( Figure 2C) . By confocal microscopy, NFAT2 was detected mostly in the nuclei of these but not Kb30 and GA cells, and, consistently with inactivation of NFAT reporter, relocated to the cytosol upon Zol treatment ( Figure 2D ). Nuclear localization of NFAT2 was also evident in B16BL6-8 and GA-PLXR tumors from vehicle-treated animals, while Zol-treated tumors displayed predominantly cytosolic NFAT2 staining ( Figure 2E Constitutive activation of NFAT2 is sustained in the SOC-driven double-negative PKB/GSK3β pathway, up-regulated and sensitive to inhibition by Zol in tumorigenic cells NFAT2 can be excluded from the nuclei and inactivated through the action GSK3β, which constitutes a substrate for inhibitory phosphorylation by PKB (15) (16) (17) . Using western blotting analysis and antibodies, reactive to the S 9 -phosphorylated GSK3β (inactive, pGSK3β) and S
473
-phosphorylated PKB (active, pAkt), we detected up-regulation of both phosphoproteins in cultured tumorigenic cells and a ~6-fold reduction of their levels by NFAT2-inhibitory dose of Zol (50 µM, 24 h) ( Figure 4A ; Supplementary Figure 6 , available at Carcinogenesis Online). Similarly, histochemical analysis revealed diminished pGSK3β and pAkt immune reactivity in melanoma lesions from Zol-treated but not control animals ( Figure 4B ). Downregulation of pGSK3β also followed over-expression of the K179M dominant-negative PKB mutant (DN-Akt) in tumorigenic cells for 48 h (Figure 4C ), suggesting that Zol inhibits NFAT2 through elimination of GSK3β repression by permanently active PKB. Indeed, overexpression of the S9A constitutively active (CA-GSK3β) GSK3β mutant or DN-Akt in tumorigenic B16BL6-8 cells for 48 h reproduced the inhibitory effect of Zol on NFAT reporter and nuclear retention of NFAT2 ( Figure 4C-F) . Inactivation of NFAT2 in Zol-treated (24 h) and DN-Akt-transfected (48 h) cells was prevented by overexpression of the K85A dominant-negative (DN-GSK3β) GSK3β mutant ( Figure 4C-F) . DN-GSK3β also rescued Zol-treated (48 h) and DN-Akt-transfected (72 h) B16BL6-8 cells from apoptosis, whereas CA-GSK3β by itself evoked cell death at 72 h ( Figure 4C and G), thus, confirming the proposed action of Zol on the doublenegative PKB/GSK3β/NFAT2 cascade. Since hyper-activity of PKB in melanoma is promoted by robust function of the SOC (9,22,23), we examined if Zol alters SOC-mediated Ca 2+ influx. By monitoring cytosolic Ca 2+ changes after SOC-stimulating depletion of intracellular Ca 2+ stores with the sarco/endoplasmic reticulum ATPase blocker thapsigargin and addition of extracellular Ca 2+ , we recorded SOC-evoked Ca 2+ rises of significantly higher rates and amplitudes in tumorigenic than in non-tumorigenic cells, and their ~3.5-to 4.5-fold inhibition by Zol in tumorigenic cells only ( Figure 5A ). Direct blockade of enhanced SOC function in tumorigenic B16BL6-8 cells by silencing the SOC regulator Stim1 inactivated PKB, reactivated GSK3β and inhibited NFAT2 48 h after transfection of Stim1 shRNA ( Figure 5B-E) . Furthermore, 72 h post-shRNA transfection, ~50% of cells underwent apoptosis ( Figure 5F ), as it occurred upon application of CA-GSK3β, DN-Akt or Zol. In contrast, co-transfection of Stim1 shRNA with DN-GSK3β did not alter NFAT2 activity and cell viability ( Figure 5C-F) , indicating that anti-apoptotic constitutive NFAT2 activity is sustained in a SOC/PKB/GSK3β pathway, up-regulated in tumorigenic cells and sensitive to SOC inhibition by Zol.
Up-regulation of the SOC/PKB/GSK3β/NFAT pathway is mediated by amplified tumorigenic cell lipid rafts, which are vulnerable to disintegration by Zol
Activation of SOC in malignant melanoma cells is promoted by Stim1 recruitment to and aggregation in cholesterol-enriched lipid rafts upon depletion of intracellular Ca 2+ stores (23) . Therefore, we examined if Zol inhibits the SOC by depleting cellular cholesterol and thereby altering raft integrity. Cholesterol measurements were conducted using the fluorescent cholesterol probe filipin and flow cytometry (23) . For quantitative raft analysis, we employed the fluorescent di-4-ANEPPDHQ (ANE) probe, which emits distinct signals from ordered (560 nm, raft) and disordered (620 nm, non-raft) membrane phases (35) . The degree of ordered microdomains was calculated as a ratio between these signals, flow cytometrically recorded at two separate channels (Supplementary Figure 7 , available at Carcinogenesis Online). Raft integrity was also studied by analyzing distribution of the glycolipid raft marker GM1 in the low-density (raft-enriched) versus high-density (non-raft) sub-cellular fractions isolated by ultracentrifugation in a gradient of sucrose. Using this paradigm, we detected ~1.5-to 2-fold higher cholesterol ( Figure 6A ) and raft levels ( Figure 6B ) in tumorigenic versus non-tumorigenic melanoma cells. Application of Zol (50 µM, 24 h) reduced cholesterol content of both cells types but, remarkably, decreased lipid raft levels ( Figure 6A and B) and triggered relocation of GM1 from the low-density to high-density fractions ( Figure 6C ) in tumorigenic cells only. The results indicated amplification of tumorigenic cell rafts, which, most probably due to high cholesterol content, are particularly sensitive to cholesterol-depleting action of Zol. Indeed, raft integrity was reconstituted by replenishing Zol-treated tumorigenic cells with exogenous cholesterol (50 µg/ml, 1 h), as reflected by recovered ANE fluorescence and GM1 distribution in the sucrose gradient ( Figure 6A-C) . Consistently, cholesterol replenishment restored Stim1 recruitment to raft-enriched fractions ( Figure 6D ) and formation of GM1-co-localized Stim1 clusters (Supplementary Figure 8 , available at Carcinogenesis Online), altered by Zol in thapsigargin-stimulated B16BL6-8 cells. These cholesterol-replenished cells also re-established robust SOC function, up-regulated pAkt and pGSK3β expression, retained NFAT2 in their nuclei and displayed diminished apoptosis ( Figure 6E -H) compared to non-replenished Zol-treated samples. The rescuing effect of the cholesterol replenishment on NFAT2 and cell survival was blunted by CA-GSK3β ( Figure 6G and H), consistently with proposed GSK3β-mediated link of hyper-active NFAT2 to raft-dependent enhanced SOC and PKB events in tumorigenic cells. In contrast in non-tumorigenic Kb30 cells, Stim1 expression and clustering were barely detectable in the rafts and not affected by Zol ( Figure 6D, Supplementary Figure 8 , available at Carcinogenesis Online). Together, our data underscore the functional relevance of amplified melanoma rafts for sustained activation of the SOC/PKB/GSK3β/NFAT2 cascade in tumorigenic cells and reveal these distinctive microdomains as a novel target for Both assays were performed in triplicates and data expressed as means + SD obtained in three independent experiments (n = 9). *P < 0.05, **P < 0.01, ***P < 0.001, Student's t-test. (E-G) NFAT-driven luciferase activity (E), NFAT2 compartmentalization (F) and cell cycle distribution (G) were determined, using luciferase assay, confocal microscopy and flow cytometry, respectively. Data of luciferase assay (E) and cell cycle analysis (G) are expressed as mean + SD of three independent experiments performed in triplicates (n = 9). (E) Typical fluorescent images acquired in one experiments of three performed are shown. Magnification ×100; scale bar 20 µm. *P < 0.05, **P < 0.01, ***P < 0.001, Student's t-test. inhibition of dysregulated NFAT2 by the clinically available generic drug Zol. Figure 7 summarizes two principal findings of our study. First, we revealed a novel pathway, in which amplified cholesterol-enriched rafts of malignant melanoma cells promote anti-apoptotic constitutive activation of NFAT2 through enhancement of SOC-and SOCdependent PKB activities, maintaining repression of the negative NFAT modulator GSK3β. Second, high sensitivity of amplified melanoma rafts to cholesterol-depleting action of Zol enables inhibition of NFAT2 by interrupting the above pathway with this agent that facilitates apoptosis in malignant cells and retards their in vivo outgrowth. The pathway was indicated by the mechanism of suppressive action of Zol on murine and human tumorigenic melanoma cell variants. Striking correlations between over-activation of NFAT2 in these malignant cells and their vulnerability to Zol and between Zolinduced apoptosis and NFAT2 inhibition (Figures 1 and 2) suggested that dysregulated NFAT2 elicits pro-survival function and constitutes a target for Zol in melanoma. The rescuing effect of the constitutively active NFAT2 mutant on NFAT function in Zol-treated cells and the fact that NFAT2 inhibition did not result from its protein loss but, rather, from nuclear exclusion (Figures 2 and 3) pointed to interruption of signal events up-stream of NFAT2. Based on the following findings (Figures 4-6 ), we concluded that nuclear exclusion of NFAT2 by Zol ultimately resulted from elimination of PKB-mediated repression of GSK3β due to disintegration of lipid rafts and subsequent inhibition of SOC. Namely, (i) Zol destabilized raft integrity, abolishing raft recruitment of Stim1 and thereby Ca 2+ influx via the SOC. This inactivated PKB and reactivated GSK3β.
Discussion
(ii) Reactivation of GSK3β, either directly or by blocking SOC or PKB, reproduced the inhibitory effect of Zol on NFAT2 and cell survival. Similar extent of NFAT2 inhibition and apoptosis, triggered by each of the above manipulation, further indicated that the lipid raft-, SOC-and PKB-driven repression of GSK3β maintained NFAT2 in constitutively active state without a need for concomitant stimulation through canonical calcineurin pathway. Finally, (iii) reconstitution of microdomains restored SOC, PKB, GSK3β and NFAT2 activities to their basal levels and diminished apoptosis, confirming that loss of raft integrity was a trigger The effect on cell survival. Cells were treated by Zol, as described in (A), except Zol-containing medium was returned to culture after cholesterol replenishment for additional 24 h. Some samples were transfected with CA-GSK3β 24 h before Zol treatment. Cell cycle was analyzed by flow cytometry and data expressed as mead + SD of three independent experiments performed in triplicates. *P < 0.05, **P < 0.01, ***P < 0.001, Student's t-test.
for down-regulation of the entire pathway in Zol-treated tumorigenic melanoma cells.
The proposed mechanism of NFAT2 dysregulation in melanoma is supported by several lines of evidence. For instance, a series of histopathology reports demonstrated repression of GSK3β in tumors, displaying elevated PKB and NFAT activities. Examples include melanoma (7, 14, 36) , lymphoma (1, 14, 37) and carcinomas of breast and hepatocellular origins (1, 14, 38, 39) . Consistently, studies in benign osteoclasts (16) and renal carcinoma cells (40) highlighted the capability of ectopically expressed hyper-active PKB to maintain GSK3β-dependent nuclear retention and activation of NFAT2, similarly to the action of endogenous hyper-active PKB in our melanoma model (Figure 4) . Furthermore, triggering of PKB-induced inhibitory phosphorylation of GSK3β by cytosolic Ca 2+ rises revealed in neurons (41) is in agreement with persistent GSK3β repression by permanently active PKB, coupled in tumorigenic melanoma cells to robust function of the SOC [ Figure 5 and (9,22,23) ]. NFAT2 is a prototypic down-stream effector of the SOC (1), the predominant Ca 2+ entry route in all non-excitable cells, stimulated by many membrane receptors and mediated by depletion of intracellular Ca 2+ stores (42) . A multitude of studies implicated strong Ca 2+ fluxes through these channels in aggressive cancer cell growth, invasion and resistance to apoptotic stimuli (9) (10) (11) (12) (13) 19, (43) (44) (45) . Up-regulation of the Stim1 and Orai1/3 protein constituents of the SOC have been evidenced in certain malignancies (10-13,43), but, importantly, increased levels of each particular constituent do not necessarily mirror tumor-promoting acceleration of Ca 2+ influx, as we (9) and Motiani et al. (10) reported in melanoma and glioblastoma, respectively. On the contrary, overexpression of Orai1 without concomitant over-expression of Stim1 reduces channel sensitivity to store-depleting signal and thereby inhibits the SOC and cancer cell growth (46) . Notably, due, in part, to abnormal accumulation of cholesterol, many types of transformed cells express increased amounts and changed composition of cholesterol-enriched lipid raft microdomains (20, (47) (48) (49) . Liquid-ordered rafts can modulate the SOC by limiting lateral diffusion and promoting interactions between different SOC-forming proteins, recruited to these microdomains (50) . Specifically, Stim1 might be targeted to the rafts, where its binding to Orai and TRPC channel constituents triggers Ca 2+ permeation (50) . Dysregulation of SOC and NFAT by modified lipid rafts of malignant cells are, therefore, predictable events, though this issue has not been explored in any cancer type. Thus, not only do we show now that cholesterol-enriched rafts are highly expressed in tumorigenic versus non-tumorigenic melanoma cell variants. Most importantly, our data provide for the first time evidence for enhanced Stim1 recruitment to these amplified rafts that augments rates and amplitudes of SOC-evoked Ca 2+ rises, linked via PKB and GSK3β to anti-apoptotic sustained activation of NFAT2 (Figures 5 and 6 ).
Clearly, a number of questions regarding this pathway remain unresolved. At present, we do not know which of the raft-associated molecules are enriched and increase docking sites for Stim1 in expanded microdomains of tumorigenic cells. It yet remains to be determined whether these molecules are Stim1-binding phosphoinositide lipids (51) and/or protein components of Ca 2+ permeation pore of the SOC (50), or septin GTPases, which drive formation of Orai1 complexes with Stim1 at the plasma membrane (52) . We also do not know how tumorigenic melanoma cells maintain their high cholesterol and lipid raft content. Remarkably, cytosolic Ca 2+ rises and PKB by themselves promote cholesterol synthesis through up-regulation of lipogenic enzymes (53, 54) . If so, it would be of the particular interest to examine whether a positive feedback loop between SOC-dependently activated PKB and biogenesis of amplified rafts exists and boosts prosurvival SOC/PKB/GSK3β/NFAT2 signaling in tumorigenic cells. Pertinent to human pathology, such a loop could be the part of aggressive melanoma phenotype, associated with insensitivity to pharmacological inhibition of BRaf. Approximately 50% of melanomas harbor oncogenically mutated BRaf, which co-operates with PKB (55) and NFAT (15, 16) in its tumor-promoting activities. Tumors, containing BRaf mutations, respond to BRaf inhibitors but shortly become drug resistant, whereas deregulation of PKB has been revealed as one of the core resistance pathways (56) . It is also noteworthy that lipid raftand Ca 2+ -dependent activation of PKB has been reported in neoplastic cells other than melanoma, that is in lung (13, 57) and colon carcinoma cells (20, 58) . Given our present data, it would as well be of the interest to determine whether this PKB activity contributes to NFATand nuclear factor-κB-driven transcription of pro-metastatic genes, coupled in both latter cell types to SOC influx (44, 45) .
It is possible that mechanisms alternative to reduction of cellular cholesterol and raft ablation might be proposed to explain interruption of the SOC/PKB/GSK3β/NFAT2 pathway by Zol, at least in part. For instance, blockade of the Zol target enzyme farnesyl diphosphate synthase impairs production of isoprenoid lipids and function of prenylation-dependent small GTPases (24) , acting as modulators of PKB and NFAT activities (14, 59) . In addition, accumulation of the farnesyl diphosphate synthase substrates is followed by their conversion to mitochondria-toxic ATP analogues and dissipation of ΔΨ m (24) . Arrest of the ΔΨ m -driven mitochondrial Ca 2+ transport could -influx via the SOC (2) and thereby Ca 2+ -driven activation of PKB (3) (12). This compromises negative regulation of NFAT2 by GSK3β (4) and preserves NFAT2 in permanently active state (5) . (B) Reduction of cellular cholesterol by the mevalonate pathway blocker Zol (6) alters raft integrity and interferes with Stim1-mediated triggering of SOC response (7) that reactivates GSK3β by inhibiting PKB (8, 9) and abolishes high basal NFAT2 activity (10) .
